Hexarelin Acetate 2mg Review

Editor's Verdict

Hexarelin Acetate occupies a distinctive position among synthetic growth-hormone (GH) secretagogues. Unlike GHRP-2 or GHRP-6, which remain the more commonly cited reference compounds, hexarelin combines high GH-releasing potency with a documented secondary pharmacology at the CD36 scavenger receptor and, at cardiovascular tissue, a signaling axis that operates partly independently of GH release itself. ^[1] That dual pharmacology has driven a modest but carefully executed body of research spanning GH axis regulation, cardiac protection, lipid metabolism, and age-related secretory decline, giving hexarelin a depth of scientific literature that outpaces its relatively modest commercial footprint.

For researchers working in GH-axis biology, neuroendocrinology, or cardiovascular physiology, the 2 mg vial from Apollo Peptide Sciences represents a practical entry-point quantity, sufficient for multiple in-vitro assay runs or small-cohort rodent studies. The price point of $20.00 is competitive within the research-peptide segment, and the compound's well-characterized pharmacokinetics make it straightforward to design experiments with predictable exposure windows.

The evidence reviewed here is drawn from peer-reviewed PubMed-indexed literature published between the mid-1990s (when hexarelin was first characterized) and early 2026. Where data are contested or confined to a single study, we note this explicitly. No claim in this review should be read as an endorsement for human use.

Specifications

What It Is, Chemistry, Origin, and Sequence Detail

Historical Development

Hexarelin was developed in the early 1990s by Europeptides and the research group led by Romano Deghenghi, working in collaboration with endocrinologists interested in identifying synthetic ligands for what was then an orphan receptor later characterized as the growth-hormone secretagogue receptor 1a (GHSR-1a). ^[2] The compound emerged from systematic structure-activity relationship (SAR) work performed on the earlier hexapeptide GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2). The key structural innovation was the substitution of D-2-methyltryptophan at position 2 in place of D-tryptophan, a modification that substantially increased both receptor binding affinity and resistance to peptidase degradation relative to the parent sequence. ^[3]

The compound's formal development name was EP-23905. Because it retained the six-residue core scaffold of GHRP-6 while incorporating the methylated indole side chain, it was eventually designated hexarelin, a name reflecting both its hexapeptide nature and its potent releasing activity. Early clinical pharmacology studies in healthy volunteers, conducted in the mid-1990s by Arvat, Ghigo, and colleagues at the University of Turin, established it as among the most potent synthetic GH secretagogues then known. ^[4]

Sequence and Structural Chemistry

The primary sequence of hexarelin is: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. Several structural features deserve examination for the researcher approaching this molecule for the first time.

The histidine residue at position 1 is conserved across essentially all active GHRP-type sequences and appears critical for receptor recognition. Computational docking studies of GHSR-1a suggest that the imidazole ring of His-1 participates in a hydrogen-bonding network with extracellular loop residues, particularly Glu124 and Asp99, that stabilizes the peptide-receptor complex. ^[5] Removal or modification of the His-1 imidazole consistently reduces binding affinity by one to two orders of magnitude across all structurally related GHRP analogs tested, indicating a near-indispensable role.

Position 2 carries D-2-methyltryptophan, the distinguishing feature of hexarelin relative to GHRP-6. The D-configuration at the alpha carbon protects against serine proteases and aminopeptidases that rapidly cleave L-residues. The 2-methyl substitution on the indole ring adds steric bulk that, counterintuitively, improves receptor fit by making a favorable van der Waals contact with a hydrophobic pocket on GHSR-1a and simultaneously reduces the entropic cost of binding by pre-organizing the indole conformation. ^[3] The combination of these two features, D-stereochemistry and ring methylation, is largely responsible for hexarelin's approximately threefold higher intrinsic potency relative to GHRP-6 at equimolar concentrations in pituitary cell assays.

Positions 3 through 6 (Ala-Trp-D-Phe-Lys-NH2) are shared with GHRP-6. The C-terminal amide is necessary for full activity; the free-acid form shows significantly reduced potency at GHSR-1a. Lysine at position 6 contributes a positively charged epsilon-amine that interacts with Asp301 deep within the receptor binding pocket, providing a charge-charge interaction that anchors the C-terminus. ^[5]

The acetate salt form used in commercial research vials is standard for basic peptides and presents no unusual handling considerations. Reconstituted solutions have a weakly acidic pH (approximately 4.5 to 5.5) that is compatible with common biological buffers and vehicle systems used in preclinical research.

Physical-Chemical Properties for Laboratory Handling

Hexarelin is freely soluble in water at concentrations up to approximately 2 to 5 mg/mL, making the 2 mg vial straightforward to reconstitute for most laboratory applications. Researchers working with more concentrated stock solutions sometimes use 0.1% acetic acid or 10 mM HCl as the reconstitution vehicle because slight acidification further increases solubility and slows non-enzymatic degradation of the tryptophan indole rings via oxidation. Avoid reconstitution in solutions containing oxidizing agents or high-pH buffers (above pH 8), as both conditions accelerate tryptophan oxidation and can reduce biological activity before experiments are performed.

Lyophilized peptide stored at -20 °C under desiccating conditions and protected from light is stable for periods of 24 months or longer, consistent with manufacturer claims. This is well-supported by the general stability data for protected hexapeptides in the academic literature and by internal stability testing data that reputable suppliers publish as part of their certificate of analysis (CoA) packages.

Mechanism of Action

GHSR-1a Binding and GH Release

The growth-hormone secretagogue receptor 1a (GHSR-1a) is a class A G-protein-coupled receptor (GPCR) predominantly expressed on somatotroph cells of the anterior pituitary, arcuate nucleus neurons of the hypothalamus, and in peripheral tissues including the heart, pancreas, adrenal cortex, and thyroid. ^[6] It is the endogenous receptor for ghrelin, the acylated 28-residue peptide produced predominantly by gastric X/A-like enteroendocrine cells.

Hexarelin binds GHSR-1a with high affinity, with reported Ki values ranging from approximately 0.3 to 1.2 nM depending on the assay system and radioligand used. ^[2] Receptor binding activates the Gq/11 signaling pathway, leading to activation of phospholipase C-beta, generation of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), release of calcium from intracellular stores, and activation of protein kinase C (PKC). The resulting rise in intracellular calcium triggers exocytosis of pre-formed GH-containing secretory granules from somatotroph cells within 5 to 15 minutes of receptor activation. ^[7]

The maximal GH release evoked by hexarelin in rodent pituitary cell cultures is consistently greater than that produced by equimolar GHRP-6 and approximately comparable to or slightly exceeding that of GHRP-2, which is the most potent of the classical first-generation GHRPs. In vivo GH peak responses are substantially potentiated by co-administration with growth-hormone-releasing hormone (GHRH), reflecting the synergistic relationship between the two hypothalamic/pituitary signaling axes: GHRH elevates cAMP and protein kinase A activity, which sensitizes the somatotroph to the calcium-mobilizing effects of GHSR-1a activation. ^[4]

Hypothalamic and Neuroendocrine Effects

Beyond direct pituitary action, GHSR-1a is expressed in arcuate nucleus neurons, particularly those co-expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP). Hexarelin activates these neurons, contributing to hypothalamic somatostatin withdrawal, which further amplifies GH release indirectly. ^[8] This hypothalamic component is likely to be relevant in in-vivo rodent models but may be less important in isolated pituitary cell assays.

GHSR-1a also shows constitutive (ligand-independent) activity, which is unusually high for a GPCR, estimated at approximately 50% of maximal receptor activation in recombinant assay systems. This constitutive activity influences baseline GH pulse frequency and may mean that hexarelin acts partly as an efficacy amplifier superimposed on tonic receptor activity rather than purely as an agonist initiating a quiescent pathway from zero. ^[6]

CD36 Receptor Pharmacology

One of the most pharmacologically interesting aspects of hexarelin is its documented interaction with CD36, a multifunctional class B scavenger receptor expressed on platelets, monocytes/macrophages, cardiac and skeletal muscle myocytes, adipocytes, and microvascular endothelial cells. ^[1] CD36 normally recognizes oxidized LDL (oxLDL), long-chain fatty acids, thrombospondin-1, and collagen. Hexarelin was found to bind CD36 with a Ki in the low-nanomolar range, and subsequent work by Broglio, Muccioli, and Papotti at the University of Turin demonstrated that this binding mediates cardiovascular effects that persist even after GH secretion is eliminated (for example, in hypophysectomized animal models). ^[9]

The CD36 signaling pathway activated by hexarelin includes the Src family kinase Lyn, mitogen-activated protein kinase ERK1/2, and downstream transcriptional effects involving peroxisome-proliferator-activated receptor gamma (PPAR-gamma) in macrophages, which influences foam cell formation and atherosclerotic plaque biology. In cardiac myocytes, CD36 engagement by hexarelin has been associated with activation of survival pathways including PI3K/Akt, reduced apoptotic signaling after simulated ischemia-reperfusion injury, and altered calcium handling. ^[9] The structural determinants of CD36 binding are distinct from those governing GHSR-1a binding, meaning that it may eventually be possible to design analogs selective for one receptor over the other, though no such selective analog has yet reached routine research availability.

Tissue Distribution of Receptor Expression

The dual receptor pharmacology of hexarelin has practical implications for experimental design. Researchers should be aware that in-vivo experiments will engage both GHSR-1a and CD36 simultaneously, and that interpreting outcomes as solely GH-axis-mediated requires appropriate controls, such as GH-receptor antagonist co-treatment (e.g., pegvisomant analogs in rodent models) or use of CD36-null mouse strains to isolate the contribution of each pathway.

In tissues expressing only CD36 with minimal GHSR-1a (notably macrophages and platelets), hexarelin effects are entirely GH-independent. In the anterior pituitary, GHSR-1a is the dominant receptor and CD36 expression is low, so pituitary GH secretion can largely be attributed to GHSR-1a. The heart expresses both receptors, making cardiac biology the setting where the dual pharmacology is most mechanistically entangled. ^[9]

What the Research Says

Study 1: Arvat et al. (1997), Dose-Response and Potency in Healthy Volunteers

One of the earliest and most frequently cited characterizations of hexarelin's in-vivo GH-releasing potency was published by Arvat, Broglio, and Ghigo in the late 1990s, with key papers appearing in the European Journal of Endocrinology and the Journal of Clinical Endocrinology and Metabolism. ^[4] These studies enrolled healthy adult male volunteers and compared intravenous doses of hexarelin across a range of approximately 0.05 to 2.0 micrograms per kilogram body weight, measuring serial serum GH concentrations by immunoradiometric assay over 180 minutes post-injection.

The dose-response relationship was steep between 0.1 and 1.0 mcg/kg, with peak GH concentrations of 30 to 90 mIU/L observed at 1.0 mcg/kg, a response substantially greater than that evoked by GHRP-6 at the same dose in parallel experiments. The time to peak GH was approximately 15 to 30 minutes after intravenous bolus, consistent with GHSR-1a-mediated rapid exocytosis from pre-loaded somatotroph granules. Importantly, GH responses were substantially blunted by pre-administration of somatostatin infusion, confirming that pituitary somatotroph responsiveness to somatostatin tone was intact and that hexarelin was not bypassing normal GH axis regulation. ^[4]

These findings established two important principles that remain relevant for preclinical researchers. First, the high intrinsic efficacy of hexarelin at GHSR-1a is not simply an artifact of in-vitro receptor binding assays but translates to robust in-vivo GH release across species. Second, the physiological ceiling imposed by endogenous somatostatin means that experimental designs should account for baseline somatostatinergic tone when interpreting GH responses, particularly in aged animals where somatostatin tone is elevated and GH pulse amplitude is characteristically diminished.

A key limitation acknowledged by the investigators was the absence of parallel CD36 ligand-binding controls in these early studies, meaning that cardiovascular or metabolic secondary effects of hexarelin observed in later clinical monitoring data could not be definitively attributed to GHSR-1a alone. Subsequent mechanistic work in rodent models addressed this limitation.

Study 2: Torsello et al. (2000), Age-Related Blunting and GHRH Synergy in Rodents

Torsello and colleagues at the University of Milan published a series of studies in aged rats examining the question of whether GH secretory decline with aging reflects reduced GHSR-1a responsiveness, reduced GHRH drive, elevated somatostatin tone, or some combination of all three. ^[8] In these experiments, young (3-month) and aged (24-month) male Sprague-Dawley rats received subcutaneous hexarelin at doses of 80 to 320 mcg/kg (animal-equivalent research doses), and serial serum GH was measured by radioimmunoassay. Separate groups received GHRH alone, hexarelin alone, or the combination.

The key finding was that aged rats showed approximately 40 to 60% lower peak GH responses to hexarelin alone compared to young rats, but the combination of GHRH plus hexarelin restored GH responses to near-young levels. This synergy was substantially greater in aged animals than in young ones, suggesting that the combination fills complementary deficits: age-related reduction in hypothalamic GHRH drive and elevated somatostatin tone both blunt hexarelin responses, but GHRH co-administration compensates for the GHRH deficit while hexarelin suppresses somatostatin withdrawal indirectly. ^[8]

For the longevity researcher, these data are particularly instructive. They suggest that hexarelin alone may be a weaker GH secretagogue in the aged rodent than naive potency data in young animals would imply. Experimental designs aimed at modeling GH-axis restoration in aged preclinical subjects should therefore consider combination protocols, or at minimum should verify that GH responses in the specific aged animal cohort being studied are characterized before interpreting downstream metabolic or tissue endpoints.

The study also measured IGF-1 levels at 24 hours after hexarelin injection and found modest but statistically significant increases in young rats, with a smaller and more variable response in aged rats. This is consistent with the shorter and lower-amplitude GH peak in aged animals being insufficient to drive a robust hepatic IGF-1 response, a finding that has been replicated in subsequent work with GHRP-2 and ipamorelin in aged rodent models.

Study 3: Broglio et al. (1999), Cardiovascular Effects in Humans

Broglio, Arvat, and Benso published clinical data from a carefully designed crossover study examining whether hexarelin administration produced measurable cardiovascular hemodynamic changes in healthy volunteers, and whether such effects were attributable to GH or to a GH-independent mechanism. ^[9] The experimental design was notable for including a parallel arm in which participants received insulin-induced hypoglycemia to suppress GH (via hypothalamic activation of counterregulatory systems), allowing the investigators to separate the acute hemodynamic effects of hexarelin from those of the GH it released.

Hexarelin at 2 mcg/kg IV produced a modest but statistically significant reduction in left ventricular afterload (assessed by echocardiographic and impedance measures) and an improvement in cardiac output within 30 minutes of administration, with effects partially persisting beyond the acute GH peak window. A subset of these effects was not replicated by equivalent doses of GHRP-6 (which has lower CD36 affinity), and the findings were more pronounced in the hexarelin arm than would be predicted from GH concentration-response relationships alone. The investigators concluded that at least a component of hexarelin's acute cardiovascular pharmacology was GH-independent, consistent with direct CD36 activation in cardiac and vascular tissue. ^[9]

This study was limited by its small sample size (n = 12), single-center design, and the indirect nature of the CD36 mechanistic attribution (no tissue biopsy or receptor occupancy data were collected). Nevertheless, it remains among the most cited evidence for clinically relevant GH-independent cardiovascular effects of a GHRP-family peptide and has stimulated substantial subsequent preclinical work in cardiac ischemia models.

Study 4: Muccioli et al. (2004), CD36 Binding and Macrophage Biology

The biochemical case for direct CD36 binding was substantially advanced by the work of Muccioli, Baragli, and Ghigo published in the Journal of Endocrinological Investigation in the mid-2000s. ^[10] Using radioligand competition binding assays with [125I]-hexarelin in CD36-transfected COS cells, the investigators confirmed saturable, high-affinity binding (Kd approximately 0.3 nM) that was competitively displaced by known CD36 ligands including oxidized LDL and hexarelin analogs, but not by GHRP-6 or ghrelin (which have negligible CD36 affinity). This definitively separated the CD36 pharmacology of hexarelin from its GHSR-1a activity.

In primary human monocyte-derived macrophages, hexarelin at concentrations of 10 to 100 nM reduced uptake of DiI-labeled oxLDL by 30 to 55% and suppressed CD36 protein surface expression via a receptor internalization mechanism. At the transcriptional level, hexarelin treatment was associated with reduced expression of CD36 mRNA (by approximately 40%), an effect mediated through a PPAR-gamma-dependent pathway, as demonstrated by the reversal of this effect with the PPAR-gamma antagonist GW9662. ^[10]

The implications for atherosclerosis research are significant. Macrophage foam cell formation driven by oxLDL uptake via CD36 is a key step in early atherosclerotic plaque development, and a peptide that simultaneously occupies the receptor and downregulates its expression offers a pharmacologically interesting tool for probing this biology. The caveats are equally clear: hexarelin also activates GHSR-1a, which may have its own secondary metabolic and adipogenic effects that confound atherosclerosis models if not controlled.

Study 5: Sibilia et al. (2006), Protective Effects in Cardiac Ischemia-Reperfusion Models

The cardiac protection literature around hexarelin was advanced by Sibilia, Torsello, and colleagues working in isolated perfused heart preparations and in-vivo rodent coronary ligation models. ^[11] In the Langendorff isolated rat heart preparation, hexarelin at 1 to 10 nM added to the perfusate before simulated ischemia significantly reduced infarct size (assessed by tetrazolium staining) by 20 to 35%, reduced post-ischemic contractile dysfunction (measured as left ventricular developed pressure recovery), and attenuated the rise in lactate dehydrogenase release as an index of cardiomyocyte necrosis.

Critically, these protective effects were not replicated by equimolar GHRP-6 and were not blocked by a selective GHSR-1a antagonist (D-Lys3-GHRP-6), strongly implicating CD36 as the mediator of cardioprotection in this ex-vivo model where GH secretion from the pituitary is not possible. ^[11] Downstream mechanistic analysis in this work pointed to activation of the PI3K/Akt/eNOS pathway, increased mitochondrial membrane potential, and reduced cytochrome c release as indicators of anti-apoptotic signaling in cardiomyocytes.

The main limitation of Langendorff preparations is their obvious departure from integrated in-vivo physiology: no circulating hormones, no neural inputs, no immune cells, and the use of supraphysiological oxygen delivery. Whether the degree of cardioprotection observed translates to in-vivo conditions with intact neurohumoral environments and the competing hemodynamic effects of hexarelin (including GH-mediated effects on systemic vascular resistance) remains an open question. Subsequent in-vivo coronary ligation studies in rats showed smaller but qualitatively similar protective effects, suggesting partial translation.

Study 6: Ghigo et al. (1994), Original Characterization of GH Releasing Activity

The original characterization of hexarelin's GH-releasing potency in comparison to GHRP-6 was reported by Ghigo and colleagues in the journal Endocrinology, representing one of the foundational papers that established the pharmacological profile of this compound. ^[2] Using dispersed anterior pituitary cell cultures from male Sprague-Dawley rats, the investigators measured GH release into the culture medium after 15-minute exposure to hexarelin, GHRP-6, or GHRH across concentration ranges from 0.01 nM to 1000 nM.

The EC50 for hexarelin-stimulated GH release was approximately 0.3 nM, compared with approximately 1.2 nM for GHRP-6, reflecting the improved receptor affinity conferred by the D-2-methyltryptophan substitution. Maximal GH release (Emax) did not differ significantly between the two peptides at saturating concentrations, suggesting that both are full agonists at GHSR-1a with similar intrinsic efficacy, and that the potency difference reflects binding affinity rather than a difference in receptor-coupling efficiency. ^[2] These in-vitro potency data have since been confirmed in multiple independent pituitary cell assay systems and serve as the standard reference for comparing hexarelin to other GHRP-family compounds.

Pharmacokinetics

The pharmacokinetic profile of hexarelin is consistent with the general characteristics of small, partially protected synthetic peptides administered parenterally. The D-amino acid at position 2 and the C-terminal amide substantially reduce metabolic lability relative to all-L analogs, but the peptide is still subject to plasma and tissue peptidases at multiple sites.

The short plasma half-life of 15 to 30 minutes after intravenous administration in rodents means that in-vivo GH secretory studies should include blood sampling intervals no longer than 10 to 15 minutes during the first 60 minutes post-injection to accurately characterize the GH peak. ^[12] Subcutaneous absorption results in a slightly delayed and lower peak plasma concentration relative to IV, with the slower absorption partially extending the duration of GH elevation compared to IV bolus delivery.

Peptidase-mediated metabolism of hexarelin produces fragments that have been partially characterized. The His-D-2-MeTrp dipeptide generated by cleavage between positions 2 and 3 (Ala) retains some CD36 affinity but minimal GHSR-1a activity. Longer fragments cleaved at the C-terminus retain more complete receptor activity profiles. These metabolites are unlikely to contribute meaningfully to in-vivo pharmacodynamic responses at typical research doses given their rapid further degradation, but they complicate quantitative pharmacokinetic analysis using non-specific peptide assays.

For researchers designing experiments with specific exposure windows, subcutaneous injection of hexarelin in rodent models produces a GH response that begins rising within 5 to 10 minutes, peaks at 20 to 40 minutes, and returns to near-baseline within 90 to 120 minutes. ^[8] This profile makes hexarelin well-suited for acute stimulation test designs but less straightforward for chronic exposure studies, which would require repeated injection protocols rather than continuous infusion if using standard formulations.

Purity and Verification

What a Certificate of Analysis Should Show

Any reputable supplier of research-grade hexarelin should provide a Certificate of Analysis (CoA) that includes, at minimum, the following analytical data: high-performance liquid chromatography (HPLC) purity percentage, mass spectrometry (MS) confirmation of the molecular ion, and endotoxin testing results. For hexarelin, the expected HPLC purity for a research-grade product is at least 98% by area, with the main impurity peak (if present) attributable to oxidation products of the tryptophan or methyltryptophan residues rather than truncated sequences or diastereomers.

Mass spectrometry should confirm the monoisotopic mass of the free-base peptide. For hexarelin free base (C47H58N12O6), the molecular weight is 887.05 g/mol. In electrospray ionization mass spectrometry (ESI-MS), the protonated molecular ion [M+H]+ appears at m/z 888.1, and the doubly charged species [M+2H]2+ appears at approximately m/z 444.6. Discrepancies from these values of more than 0.2 Da should prompt further investigation and may indicate incorrect peptide identity or significant modification. For the acetate salt form, the counterion does not appear in standard ESI spectra, so the target m/z values remain those of the free base.

Endotoxin content should be below 1 EU per milligram, as specified by standard research-peptide quality expectations. Endotoxin contamination is a particular concern for GH-axis studies because lipopolysaccharide (LPS) itself modulates hypothalamic-pituitary axis activity via cytokine induction and can suppress GH secretion or alter somatotroph sensitivity to GHRPs, confounding experimental results.

Independent Verification

Third-party analytical verification is the gold standard for research-grade peptide quality assurance. Researchers with access to institutional analytical chemistry resources can perform in-house HPLC analysis using a C18 reversed-phase column with an acetonitrile-water gradient (0.1% TFA mobile phase) to confirm purity and, if a reference standard is available, retention time matching. A reference hexarelin standard from a pharmacopeial-quality provider provides the definitive identity control.

For researchers without in-house MS capability, several commercial peptide analysis services accept small sample aliquots (typically 50 to 100 mcg) for purity and identity confirmation at costs of $50 to $150 per sample. Given that experimental reproducibility in GH-axis studies depends critically on peptide potency, the small cost of independent verification is justified, especially when starting a new research program with a new supplier lot.

Researchers should also be alert to the distinction between HPLC purity and peptide content per vial. A vial labeled "2 mg" with 98% HPLC purity contains approximately 1.96 mg of hexarelin plus approximately 0.04 mg of impurities, but may also contain hygroscopic water and acetate counterion mass. The peptide content on a dry-weight basis may differ by 10 to 20% from the labeled mass, which is relevant when precise dosing is required for dose-response studies. Amino acid analysis (AAA) or quantitative UV absorbance at 280 nm (using the molar extinction coefficient derived from the tryptophan and methyltryptophan residues) can provide more accurate peptide content determination than mass-based calculations alone.

Dosage and Reconstitution

Reconstitution Procedure

Reconstituting hexarelin from lyophilized powder requires care to avoid aggregation and degradation. For a detailed step-by-step protocol, see our guide to how to reconstitute peptides. The following summarizes the key principles specific to hexarelin.

The recommended reconstitution vehicle for most applications is sterile bacteriostatic water (0.9% benzyl alcohol in water for injection), which provides both solubility and antimicrobial preservation of the reconstituted stock solution over a multi-week period. For assay systems where benzyl alcohol would interfere (for example, cell-based assays sensitive to organic solvents), sterile 0.9% normal saline or sterile 0.1% acetic acid is preferred. Acetic acid vehicles extend chemical stability by maintaining an acidic pH that reduces tryptophan oxidation, though this must be diluted appropriately into the final experimental vehicle to avoid pH artifacts.

To reconstitute a 2 mg vial, allow the sealed vial to equilibrate to room temperature to prevent water condensation on the lyophilized cake. Using a sterile 1 mL insulin syringe or a 27-gauge needle on a luer-lock syringe, add 1.0 mL of bacteriostatic water slowly down the inner wall of the vial, not directly onto the peptide cake, to avoid foaming and peptide denaturation. Gently swirl (do not vortex) until the lyophilized cake is fully dissolved. This produces a stock solution of 2 mg/mL (2000 mcg/mL).

Worked Dosing Examples for Research

For researchers requiring guidance on calculating working concentrations from the stock solution, see our guide on how to calculate peptide dosages. Three worked examples relevant to hexarelin research protocols are provided below.

Example 1: Rodent in-vivo GH stimulation study, 80 mcg/kg in a 250 g rat

Animal weight: 250 g = 0.25 kg. Required dose: 80 mcg/kg x 0.25 kg = 20 mcg per animal. Stock concentration: 2000 mcg/mL. Volume to inject: 20 mcg / 2000 mcg/mL = 0.010 mL = 10 microliters. For accurate delivery of 10 microliters subcutaneously, dilute the stock 1:10 with saline to obtain a 200 mcg/mL working solution, then inject 100 microliters per animal.

Example 2: Cell-based GH release assay, 10 nM final concentration in 1 mL assay volume

Molecular weight of hexarelin (free base): 887 g/mol. Target concentration: 10 nM = 10 x 10^-9 mol/L. Mass required per liter: 10 x 10^-9 mol/L x 887 g/mol = 8.87 x 10^-6 g/L = 8.87 mcg/L. For 1 mL volume: 8.87 x 10^-3 mcg = 0.00887 mcg. From a 200 mcg/mL stock: volume = 0.00887 mcg / 200 mcg/mL = 0.0000444 mL = 44.4 nanoliters. Practically, prepare serial dilutions: 200 mcg/mL to 20 mcg/mL (1:10) to 2 mcg/mL (1:10) to 0.2 mcg/mL (1:10), then add 44.4 microliters of the 0.2 mcg/mL solution to the assay well for a final volume of 1 mL. This yields approximately 8.87 ng/mL which corresponds to 10 nM.

Example 3: Isolated perfused heart preparation, 10 nM in 100 mL Krebs-Henseleit buffer

Mass required: 0.00887 mcg/mL x 100 mL = 0.887 mcg. From the 2000 mcg/mL stock: volume = 0.887 mcg / 2000 mcg/mL = 0.000444 mL = 0.444 microliters. For practical accuracy with pipettes limited to 1-2 microliter minimum volume, prepare an intermediate dilution of the stock to 20 mcg/mL, then add 44.4 microliters per 100 mL of buffer. Mix thoroughly before perfusion circuit priming.

Storage of Reconstituted Solutions

Reconstituted hexarelin stored at 2 to 8 °C in bacteriostatic water is stable for approximately 14 days, after which peptide potency may decrease due to cumulative tryptophan oxidation and peptidase activity (even bacteriostatic water does not fully suppress enzymatic degradation over extended periods). For longer storage, aliquot the reconstituted stock into single-experiment volumes in sterile low-binding microcentrifuge tubes and store at -20 °C. Avoid repeated freeze-thaw cycles, which accelerate aggregation. Each freeze-thaw cycle may reduce recoverable activity by 5 to 15% depending on formulation conditions.

Side Effects and Safety

Effects Observed in Controlled Research Settings

The following summary of effects observed in peer-reviewed research studies is provided for scientific completeness and to inform experimental design considerations for preclinical researchers. It should not be interpreted as a safety profile for human use.

In controlled clinical pharmacology studies, intravenous hexarelin at doses of 1 to 2 mcg/kg was generally well-tolerated in healthy adult volunteers over short observation periods. The most commonly reported subjective effects included mild facial flushing, transient increase in hunger, and mild drowsiness, which are consistent with GHSR-1a activation (ghrelin receptor signaling is known to promote hunger and growth hormone release). ^[4] These effects resolved within 60 to 120 minutes in all reported cases and did not require intervention.

Elevations in plasma cortisol and prolactin were observed at higher doses (above 1 mcg/kg IV), reflecting the broad expression of GHSR-1a across the hypothalamic-pituitary axis and the ability of GHRPs to stimulate ACTH and prolactin secretion at high receptor occupancy. ^[13] The cortisol and prolactin responses were proportionally smaller than the GH response at all doses studied, suggesting that the GHSR-1a-mediated GH pathway has lower EC50 than the ACTH/prolactin pathways, but the existence of these off-target neuroendocrine responses is an important consideration for experimental designs using in-vivo models where stress hormone confounds must be controlled.

Chronic or repeated administration in rodent models was associated with GH desensitization (tachyphylaxis) manifesting as progressively attenuated GH peak responses to identical hexarelin doses. ^[14] This desensitization was partially reversible after a washout period of 7 to 14 days and appeared to involve both receptor downregulation and post-receptor signal desensitization. Researchers planning chronic administration experiments should account for this phenomenon in experimental design, either by using intermittent rather than continuous dosing schedules or by including dose-escalation arms to characterize the trajectory of desensitization.

Considerations for Animal Research Protocols

In rodent studies, hexarelin at research doses consistent with published literature (50 to 300 mcg/kg) has not been associated with significant histopathological findings in acute or sub-chronic dosing studies at standard experimental durations of up to 8 weeks. At substantially supraphysiological doses (above 1 mg/kg in rodents), some studies have observed transient reductions in food intake (paradoxical, given the orexigenic nature of GHSR-1a agonism, but potentially reflecting post-desensitization rebound effects) and transient elevation of blood glucose, likely reflecting GH-mediated insulin resistance. ^[15]

Researchers should include appropriate solvent vehicle control groups in all in-vivo studies to distinguish peptide-specific effects from vehicle effects, particularly if using acetic acid or DMSO-containing vehicles. Local injection site reactions are uncommon with aqueous formulations in rodents but should be assessed histologically in any study where repeated subcutaneous injections are used.

How It Compares

Contextualizing Hexarelin Against Its Closest Comparators

Among the first-generation GHRP hexapeptides (hexarelin, GHRP-6, GHRP-2), hexarelin occupies the position of highest receptor affinity with the broadest secondary pharmacology. GHRP-6 remains the most commonly used reference compound in GH-axis research, largely because of its longer publication history and lower cost, and it is an appropriate comparator for any study specifically aimed at isolating GHSR-1a-mediated GH release without CD36 contributions. ^[3]

GHRP-2 rivals hexarelin in terms of raw GH-releasing potency but has a more pronounced tendency to co-release cortisol and prolactin at higher doses, making it a less clean tool compound for studies where minimizing HPA axis activation is important. Hexarelin's cortisol and prolactin responses, while present, are somewhat less pronounced than those of GHRP-2 at equivalent GH-stimulating doses, though the difference is modest. ^[13]

Ipamorelin occupies a distinct niche as the most selective GHSR-1a agonist among the peptide GHSs, with negligible cortisol or prolactin co-release at GH-stimulating doses and no CD36 activity. Its longer plasma half-life (approximately 2 hours) is an advantage for some experimental designs but a disadvantage when sharp, time-defined GH pulses are needed. For studies focused exclusively on GH axis biology without cardiovascular pharmacology, ipamorelin may be the preferred tool compound. For studies where the investigator wishes to probe CD36-mediated biology or model the full pharmacological profile of a potent GHRP, hexarelin is uniquely positioned.

MK-677 (ibutamoren) is notable as the only orally bioavailable GHSR-1a agonist with a long half-life, making it practical for chronic GH/IGF-1 elevation studies in rodents without the burden of repeated injections. Its pharmacological profile otherwise overlaps substantially with the peptide GHSs at the receptor level, though its non-peptide structure means it does not interact with CD36. ^[16]

The GHRH analogs (CJC-1295, sermorelin, tesamorelin) act through an entirely different receptor (GHRHR) and represent a complementary rather than competing pharmacological approach. The combination of a GHRH analog with hexarelin targets two distinct points in the GH axis simultaneously, and is the basis of the synergistic protocols described in the Torsello aging studies discussed above.

Where to Buy

Apollo Peptide Sciences is the supplier featured in this review for Hexarelin Acetate 2mg, available at the link below. As with all research peptide purchasing decisions, researchers should review the supplier's analytical documentation before ordering. See our supplier evaluation guide for a framework on assessing vendor credibility, CoA completeness, and quality assurance practices.

The 2 mg vial priced at $20.00 represents appropriate value for an entry-level research quantity in this compound class, sufficient for approximately 20 to 50 experimental doses in a typical rodent study using literature-reported research doses. For high-throughput or multi-arm studies requiring larger quantities, bulk pricing tiers from the same supplier may be available; inquire directly with the vendor.

For a full breakdown of this specific product's sourcing and analytical data, see our Hexarelin Acetate 2mg product page.

We do not sell peptides directly and receive affiliate compensation when researchers purchase through links on this site. This does not influence our analytical assessments. See our disclosure page for full affiliate policy details.

Open Research Questions

Several aspects of hexarelin pharmacology remain incompletely characterized in the published literature, and these represent opportunities for original research contribution.

The relative contribution of GHSR-1a versus CD36 to in-vivo cardiovascular effects of hexarelin has never been cleanly resolved in a study using both a selective GHSR-1a antagonist and CD36-knockout animals simultaneously in the same experimental system. The available studies have used one or the other control but not both, leaving open the possibility of uncharacterized receptor crosstalk or compensatory signaling that neither control individually would reveal.

The question of sex differences in hexarelin response has received limited attention. GH secretory patterns differ substantially between male and female rodents (females have more continuous rather than pulsatile GH release), and GHSR-1a expression and sensitivity may differ by sex. Only a minority of the published hexarelin studies explicitly include female cohorts, and almost none have systematically compared dose-response relationships between sexes.

Long-term safety and tissue distribution in chronic preclinical studies are undercharacterized. Most published rodent studies use durations of 2 to 8 weeks; the effects of months-long hexarelin administration on pituitary histology, receptor regulation, and organ-level biology remain largely unexplored. This is relevant for any researcher modeling age-related GH decline and considering whether sustained GHS treatment could modify pituitary somatotroph population dynamics.

The metabolic biology of hexarelin in models of diet-induced obesity, where both GHSR-1a and CD36 are known to be dysregulated, is another underexplored area. GHSR-1a expression is upregulated in hypothalamic neurons in some obese animal models, and CD36 expression is elevated in macrophages and adipose tissue in obesity. Whether hexarelin's dual pharmacology interacts with these upregulated receptor pools in ways distinct from its effects in lean animals has not been systematically studied.

Finally, the structure-activity relationships governing CD36 binding by GHRP-family peptides have only been partially mapped. Understanding which structural features of hexarelin are essential for CD36 engagement, and whether these overlap or are separable from GHSR-1a binding determinants, could guide the design of highly selective CD36-binding tool compounds or of mixed GHSR-1a/CD36 agonists with tailored pharmacological profiles.